The LYMfit Study: Exercise Training to Prevent Cardiovascular Disease in Lymphoma Survivors
The LYMfit Study: Exercise Training to Prevent Cardiovascular Disease in Lymphoma Survivors
This study aims to compare the effects of aerobic exercise with or without addition of resistance exercise to usual care in individuals treated with anthracyclines for lymphomas and to compare exercise effects to age- and sex-matched individuals with no prior history of malignant diseases.
In this study, a comparison of the exercise effects between individuals previously treated for specific lymphoma diagnoses and individuals with no history of cancer will be conducted. Therefore, in addition to a randomized controlled trial in individuals with a previous lymphoma diagnosis (i.e., exercise groups and a non-exercising control group), a reference group comprising age- and sex-matched individuals with no history of a cancer diagnosis will also be included. Participants in the reference group will undergo the same exercise intervention as the aerobic exercise group. This study recruits through invitation only.
The primary endpoint in this study is the change in cardiorespiratory fitness, assessed as VO2peak. Secondary endpoints include common risk factors for cardiovascular disease and cardiometabolic health, other variables derived from the cardiopulmonary exercise test and lung function assessments, and muscle cellular endpoints from muscle biopsies obtained from m. vastus lateralis, in addition to patient-reported outcomes.
Inclusion Criteria Lymphoma participants:
Inclusion Criteria Lymphoma participants and non-cancer reference group:
Exclusion Criteria Lymphoma participants:
Exclusion Criteria Lymphoma participants and non-cancer reference group:
tormodsn@nih.no95069857 ext. 0047
helena.igelstrom@neuro.uu.se729999599 ext. 0046
anna.km.henriksson@uu.se709394175 ext. 0046